CompletedPhase 2NCT03456882

The Effect of RNS60 on ALS Biomarkers

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mario Negri Institute for Pharmacological Research
Principal Investigator
Ettore Beghi, MD
IRCCS Istituto di ricerche farmacologiche Mario Negri di Milano
Intervention
RNS60(drug)
Enrollment
147 enrolled
Eligibility
18-80 years · All sexes
Timeline
20172021

Study locations (23)

Collaborators

ALS Association · Get Out Onlus

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03456882 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials